Novartis receives approval for new Afinitor breast cancer indication
2 August 2012 09:05 in Pharmaceutical Company Product News
Novartis has been granted European regulatory approval for its oncology therapy Afinitor in a new indication.
The European Commission has approved the drug for use in combination with exemestane against hormone receptor-positive, HER2/neu-negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.
This is the most common form of advanced breast cancer, with Afinitor being the first mTOR inhibitor therapy to be approved for use against the disease.
Data from the phase III Bolero-2 trial demonstrated that the product can significantly improve survival rates among patients.
Herve Hoppenot, president at Novartis Oncology, said: "Treatment with Afinitor gives women a new option in the battle against this advanced form of breast cancer, where there remains a significant unmet need."
Last month, the company published its financial report for the second quarter of 2012, during which it experienced a one percent year-on-year growth in sales.
Other news stories from 02/08/2012
Related news
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency
